Teva Pharmaceuticals - Wikipedia
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Teva - Smart Woman Securities
Teva and Active Biotech Announce Concerto Trial of Laquinimod did not Meet Primary Endpoint | Pharmasources.com
Teva drops laquinimod for most common form of MS after failed trial - PMLiVE
Teva: Leverage A Concern (NYSE:TEVA) | Seeking Alpha
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
The top 10 leading biotech companies | biotechworldwide.net
Teva and Active Biotech Expand Investigational MS Treatment Program
Tweets with replies by Teva Pharmaceuticals (@TevaUSA) / Twitter
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Active Biotech: Latest News | Tracxn
Teva and Active Signs Agreement to Study By CIOReview Team
Active Biotech provides update on laquinimod in Huntington's disease - Huntington's Disease News
CHMP says no to Laquinimod
2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, ppt download
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails
Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint - Chemdiv
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Active Biotech - News, Articles etc. - European Pharmaceutical Review
Active Biotech Pivots Away from MS and Huntington's Disease, Goes in New Direction | BioSpace
Teva Pharmaceutical Industries Ltd - News, Articles etc. - European Pharmaceutical Review
